IMEIK(SZ:300896) Xin Lang Cai Jing·2025-08-27 05:54Company Overview - Aimeike Technology Co., Ltd. is located at 21st Floor, C Building, Shimao Tower, 92 Jianguo Road, Chaoyang District, Beijing, established on June 9, 2004, and listed on September 28, 2020 [2] - The company's main business involves the research, production, and sales of biomedical soft tissue repair materials [2] - Revenue composition includes: 57.27% from solution injection products, 37.97% from gel injection products, 3.01% from others, 1.50% from freeze-dried powder injection products, and 0.26% from facial implant threads [2] Stock Performance - As of August 27, Aimeike's stock price decreased by 2.02%, trading at 193.70 CNY per share, with a total market capitalization of 58.612 billion CNY [1] - Year-to-date, the stock price has increased by 8.38%, with a 2.76% rise over the last five trading days, 2.19% over the last 20 days, and 7.76% over the last 60 days [2] Financial Performance - For the first half of 2025, Aimeike reported revenue of 1.299 billion CNY, a year-on-year decrease of 21.59%, and a net profit attributable to shareholders of 789 million CNY, down 29.57% year-on-year [2] Shareholder Information - As of August 20, the number of Aimeike shareholders was 55,600, a decrease of 0.09% from the previous period, with an average of 3,753 circulating shares per person, an increase of 0.09% [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.525 billion CNY, with 2.650 billion CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the sixth largest shareholder with 6.9808 million shares, a decrease of 1.0906 million shares from the previous period [3] - Other notable shareholders include Huabao CSI Medical ETF and E Fund Growth Enterprise Board ETF, with changes in their holdings noted [3]